Multiple myeloma: Current perspectives

Clinics in Laboratory Medicine

Volumn 31, Issue 4, 2011, Pages 699-724

  Slovak, Marilyn L ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

Cytogenetics; Fluorescence in situ hybridization; Microarray; Monoclonal gammopathy; Multiple myeloma; Plasma cell dyscrasia

Indexed keywords

BORTEZOMIB; CYCLIN D1; DEXAMETHASONE; LENALIDOMIDE; M PROTEIN; PARAPROTEIN; THALIDOMIDE;

BONE MARROW SUPPRESSION; BONE MARROW TUMOR; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CELL FUNCTION; CELL PROLIFERATION; CELL TRANSFORMATION; CHROMOSOME 1; CHROMOSOME 12; CHROMOSOME 17; CHROMOSOME 8; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; COMORBIDITY; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; ETHNIC DIFFERENCE; FAMILY HISTORY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENETIC RISK; HIGH RISK PATIENT; HUMAN; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; OBESITY; ONSET AGE; OVERALL SURVIVAL; PATHOGENESIS; PATIENT CARE; PLASMA CELL; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX RATIO; SINGLE NUCLEOTIDE POLYMORPHISM; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

CYTOGENETIC ANALYSIS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; PARAPROTEINEMIAS;

EID: 82355184541     PISSN: 02722712     EISSN: 15579832     Source Type: Journal    
DOI: 10.1016/j.cll.2011.08.009     Document Type: Review

References (118)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Bray F., Sankila R., Ferlay J., et al. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002, 38:99-166.
3. Alexander D.D., Mink P.J., Adami H.O., et al. Multiple myeloma: a review of the epidemiologic literature. Int J Cancer 2007, 120(Suppl 12):40-61.
4. Landgren O., Kyle R.A., Pfeiffer R.M., et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009, 113:5412-5417.
5. Weiss B.M., Abadie J., Verma P., et al. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009, 113:5418-5422.
6. Dimopoulos M., Kyle R., Fermand J.P., et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011, 117:4701-4705.
7. Bergsagel P.L., Kuehl W.M., Zhan F., et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005, 106:296-303.
8. Landgren O., Kyle R.A., Rajkumar S.V. From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention. Clin Cancer Res 2011, 17:1243-1252.
9. Gonzalez D., van der Burg M., Garcia-Sanz R., et al. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 2007, 110:3112-3121.
10. Kyle R.A., Rajkumar S.V. Multiple myeloma. Blood 2008, 111:2962-2972.
11. Bergsagel P.L., Kuehl W.M. Chromosome translocations in multiple myeloma. Oncogene 2001, 20:5611-5622.
12. Fonseca R., Bailey R.J., Ahmann G.J., et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002, 100:1417-1424.
13. Sirohi B., Powles R. Epidemiology and outcomes research for MGUS, myeloma and amyloidosis. Eur J Cancer 2006, 42:1671-1683.
14. Prince H.M., Schenkel B., Mileshkin L. Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide. Leukemia 2007, 21:818-820.
15. Kumar S.K., Rajkumar S.V., Dispenzieri A., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111:2516-2520.
16. Lokhorst H., Einsele H., Vesole D., et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol 2010, 28:4521-4530.
17. Rajkumar S.V., Harousseau J.L., Durie B., et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011, 117:4691-4695.
18. Munshi N.C., Anderson K.C., Bergsagel P.L., et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011, 117:4696-4700.
19. Avet-Loiseau H., Li C., Magrangeas F., et al. Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 2009, 27:4585-4590.
20. Annunziata C.M., Hernandez L., Davis R.E., et al. A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood 2011, 117:2396-2404.
21. Dewald G.W., Kyle R.A., Hicks G.A., et al. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 1985, 66:380-390.
22. Sawyer J.R., Waldron J.A., Jagannath S., et al. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995, 82:41-49.
23. Lai J.L., Zandecki M., Mary J.Y., et al. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood 1995, 85:2490-2497.
24. Smadja N.V., Fruchart C., Isnard F., et al. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia 1998, 12:960-969.
25. Rajkumar S.V., Fonseca R., Dewald G.W., et al. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet 1999, 113:73-77.
26. Calasanz M.J., Cigudosa J.C., Odero M.D., et al. Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations. Genes Chromosomes Cancer 1997, 18:84-93.
27. Seong C., Delasalle K., Hayes K., et al. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol 1998, 101:189-194.
28. Dewald G.W., Therneau T., Larson D., et al. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood 2005, 106:3553-3558.
29. Fonseca R., Debes-Marun C.S., Picken E.B., et al. The recurrent IGH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 2003, 102:2562-2567.
30. Zhan F., Huang Y., Colla S., et al. The molecular classification of multiple myeloma. Blood 2006, 108:2020-2028.
31. Carrasco D.R., Tonon G., Huang Y., et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006, 9:313-325.
32. Xiong W., Wu X., Starnes S., et al. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood 2008, 112:4235-4246.
33. Walker B.A., Leone P.E., Chiecchio L., et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 2010, 116:e56-e65.
34. Shaughnessy J.D., Zhan F., Burington B.E., et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007, 109:2276-2284.
35. Broyl A., Hose D., Lokhorst H., et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 2010, 116:2543-2553.
36. Mercer B.R., Rayeroux K.C. Detection of chromosome abnormalities using cytoplasmic immunoglobulin staining and FISH in myeloma. Methods Mol Biol 2011, 730:159-171.
37. Slovak M.L., Bedell V., Pagel K., et al. Targeting plasma cells improves detection of cytogenetic aberrations in multiple myeloma: phenotype/genotype fluorescence in situ hybridization. Cancer Genet Cytogenet 2005, 158:99-109.
38. Gonzalez D., Gonzalez M., Alonso M.E., et al. Incomplete DJH rearrangements as a novel tumor target for minimal residual disease quantitation in multiple myeloma using real-time PCR. Leukemia 2003, 17:1051-1057.
39. Sarasquete M.E., Garcia-Sanz R., Gonzalez D., et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica 2005, 90:1365-1372.
40. Wuilleme S., Robillard N., Lode L., et al. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia 2005, 19:275-278.
41. Cremer F.W., Bila J., Buck I., et al. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosomes Cancer 2005, 44:194-203.
42. Fonseca R., Bergsagel P.L., Drach J., et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009, 23:2210-2221.
43. Smadja N.V., Bastard C., Brigaudeau C., et al. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001, 98:2229-2238.
44. Smadja N.V., Leroux D., Soulier J., et al. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases. Genes Chromosomes Cancer 2003, 38:234-239.
45. Kuehl W.M., Bergsagel P.L. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002, 2:175-187.
46. Gabrea A., Martelli M.L., Qi Y., et al. Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors. Genes Chromosomes Cancer 2008, 47:573-590.
47. Tonon G. Molecular pathogenesis of multiple myeloma. Hematol Oncol Clin North Am 2007, 21:985-1006. vii.
48. Fonseca R., Barlogie B., Bataille R., et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004, 64:1546-1558.
49. Kuehl W.M., Bergsagel P.L. Early genetic events provide the basis for a clinical classification of multiple myeloma. Hematology Am Soc Hematol Educ Program 2005, 346-352.
50. Keats J.J., Reiman T., Maxwell C.A., et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003, 101:1520-1529.
51. Santra M., Zhan F., Tian E., et al. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood 2003, 101:2374-2376.
52. Avet-Loiseau H., Facon T., Grosbois B., et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002, 99:2185-2191.
53. Karlin L., Soulier J., Chandesris O., et al. Clinical and biological features of t(4;14) multiple myeloma: a prospective study. Leuk Lymphoma 2011, 52:238-246.
54. Gertz M.A., Lacy M.Q., Dispenzieri A., et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005, 106:2837-2840.
55. Gutierrez N.C., Castellanos M.V., Martin M.L., et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 2007, 21:143-150.
56. Avet-Loiseau H., Leleu X., Roussel M., et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010, 28:4630-4634.
57. Hoyer J.D., Hanson C.A., Fonseca R., et al. The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study. Am J Clin Pathol 2000, 113:831-837.
58. Garand R., Avet-Loiseau H., Accard F., et al. t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia 2003, 17:2032-2035.
59. Fonseca R., Blood E.A., Oken M.M., et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 2002, 99:3735-3741.
60. Rasmussen T., Kuehl M., Lodahl M., et al. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 2005, 105:317-323.
61. Chng W.J., Gonzalez-Paz N., Price-Troska T., et al. Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia 2008, 22:2280-2284.
62. Shaughnessy J., Gabrea A., Qi Y., et al. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood 2001, 98:217-223.
63. Kumar S.K., Mikhael J.R., Buadi F.K., et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009, 84:1095-1110.
64. Fonseca R., Blood E., Rue M., et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003, 101:4569-4575.
65. Ross F.M., Chiecchio L., Dagrada G., et al. The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. Haematologica 2010, 95:1221-1225.
66. Avet-Loiseau H., Malard F., Campion L., et al. Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?. Blood 2011, 117:2009-2011.
67. Hurt E.M., Wiestner A., Rosenwald A., et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004, 5:191-199.
68. Nair B., van R.F., Shaughnessy J.D., et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood 2010, 115:4168-4173.
69. Krummel K.A., Roberts L.R., Kawakami M., et al. The characterization of the common fragile site FRA16D and its involvement in multiple myeloma translocations. Genomics 2000, 69:37-46.
70. Jenner M.W., Leone P.E., Walker B.A., et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood 2007, 110:3291-3300.
71. Le Baccon P., Leroux D., Dascalescu C., et al. Novel evidence of a role for chromosome 1 pericentric heterochromatin in the pathogenesis of B-cell lymphoma and multiple myeloma. Genes Chromosomes Cancer 2001, 32:250-264.
72. Sawyer J.R., Tricot G., Mattox S., et al. Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood 1998, 91:1732-1741.
73. Sawyer J.R., Tricot G., Lukacs J.L., et al. Genomic instability in multiple myeloma: evidence for jumping segmental duplications of chromosome arm 1q. Genes Chromosomes Cancer 2005, 42:95-106.
74. Hanamura I., Stewart J.P., Huang Y., et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006, 108:1724-1732.
75. Qazilbash M.H., Saliba R.M., Ahmed B., et al. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant 2007, 13:1066-1072.
76. Wu K.L., Beverloo B., Velthuizen S.J., et al. Sequential analysis of chromosome aberrations in multiple myeloma during disease progression. Clin Lymphoma Myeloma 2007, 7:280-285.
77. Leone P.E., Walker B.A., Jenner M.W., et al. Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin Cancer Res 2008, 14:6033-6041.
78. Chang H., Qi X., Jiang A., et al. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Bone Marrow Transplant 2010, 45:117-121.
79. Chang H., Jiang A., Qi C., et al. Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Leuk Lymphoma 2010, 51:2084-2091.
80. Chng W.J., Gertz M.A., Chung T.H., et al. Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma. Leukemia 2010, 24:833-842.
81. Inoue J., Otsuki T., Hirasawa A., et al. Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma. Am J Pathol 2004, 165:71-81.
82. Shaughnessy J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology 2005, 10(Suppl 1):117-126.
83. Zhan F., Colla S., Wu X., et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through. Blood 2007, 109:4995-5001.
84. Rosinol L., Carrio A., Blade J., et al. Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma. Br J Haematol 2005, 130:729-732.
85. Fonseca R., Van Wier S.A., Chng W.J., et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia 2006, 20:2034-2040.
86. Nemec P., Zemanova Z., Greslikova H., et al. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy. Biol Blood Marrow Transplant 2010, 16:548-554.
87. Avet-Loiseau H., Gerson F., Magrangeas F., et al. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 2001, 98:3082-3086.
88. Shou Y., Martelli M.L., Gabrea A., et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci USA 2000, 97:228-233.
89. Guikema J.E., Hovenga S., Vellenga E., et al. CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease. Br J Haematol 2003, 121:36-43.
90. Moreau P., Robillard N., Jego G., et al. Lack of CD27 in myeloma delineates different presentation and outcome. Br J Haematol 2006, 132:168-170.
91. Morgan T.K., Zhao S., Chang K.L., et al. Low CD27 expression in plasma cell dyscrasias correlates with high-risk disease: an immunohistochemical analysis. Am J Clin Pathol 2006, 126:545-551.
92. Shaughnessy J., Tian E., Sawyer J., et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood 2000, 96:1505-1511.
93. Zojer N., Konigsberg R., Ackermann J., et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2000, 95:1925-1930.
94. Chiecchio L., Dagrada G.P., Ibrahim A.H., et al. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. Haematologica 2009, 94:1708-1713.
95. Kapanadze B., Kashuba V., Baranova A., et al. A cosmid and cDNA fine physical map of a human chromosome 13q14 region frequently lost in B-cell chronic lymphocytic leukemia and identification of a new putative tumor suppressor gene, Leu5. FEBS Lett 1998, 426:266-270.
96. Drach J., Ackermann J., Fritz E., et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 1998, 92:802-809.
97. Chang H., Qi C., Yi Q.L., et al. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 2005, 105:358-360.
98. Avet-Loiseau H., Li J.Y., Godon C., et al. P53 deletion is not a frequent event in multiple myeloma. Br J Haematol 1999, 106:717-719.
99. Neri A., Baldini L., Trecca D., et al. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 1993, 81:128-135.
100. Avet-Loiseau H. Role of genetics in prognostication in myeloma. Best Pract Res Clin Haematol 2007, 20:625-635.
101. Avet-Loiseau H. Ultra high-risk myeloma. Hematology Am Soc Hematol Educ Program 2010, 2010:489-493.
102. Reece D., Song K.W., Fu T., et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 2009, 114:522-525.
103. Dimopoulos M.A., Kastritis E., Christoulas D., et al. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia 2010, 24:1769-1778.
104. Klein U., Jauch A., Hielscher T., et al. Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. Cancer 2011, 117:2136-2144.
105. Govindarajan R., Jagannath S., Flick J.T., et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol 1996, 95:349-353.
106. Nilsson T., Nilsson L., Lenhoff S., et al. MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q). Genes Chromosomes Cancer 2004, 41:223-231.
107. Jacobson J., Barlogie B., Shaughnessy J., et al. MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants. Br J Haematol 2003, 122:430-440.
108. Barlogie B., Tricot G., Haessler J., et al. Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989. Blood 2008, 111:94-100.
109. Decaux O., Lode L., Magrangeas F., et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. J Clin Oncol 2008, 26:4798-4805.
110. Annunziata C.M., Davis R.E., Demchenko Y., et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007, 12:115-130.
111. Keats J.J., Fonseca R., Chesi M., et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007, 12:131-144.
112. Demchenko Y.N., Glebov O.K., Zingone A., et al. Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood 2010, 115:3541-3552.
113. Chapman M.A., Lawrence M.S., Keats J.J., et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011, 471:467-472.
114. Munshi N.C., Avet-Loiseau H. Genomics in multiple myeloma. Clin Cancer Res 2011, 17:1234-1242.
115. Gutierrez N.C., Sarasquete M.E., Misiewicz-Krzeminska I., et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 2010, 24:629-637.
116. Johnson D.C., Corthals S.L., Walker B.A., et al. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol 2011, 29:797-804.
117. Shaughnessy J., Jacobson J., Sawyer J., et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood 2003, 101:3849-3856.
118. Barlogie B., Anaissie E., van Rhee F., et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007, 138:176-185.